Treating metastatic osteosarcoma (OS) remains a challenge in oncology. Current treatment strategies target the primary tumour rather than metastases and have a limited efficacy in the treatment of metastatic disease. Metastatic cells have specific features that render them less sensitive to therapy and targeting these features might enhance the efficacy of current treatment. A detailed study of the biological characteristics and behaviour of metastatic OS cells may provide a rational basis for innovative treatment strategies. The aim of this review is to give an overview of the biological changes in metastatic OS cells and the preclinical and clinical efforts targeting the different steps in OS metastases and how these contribute to designi...
Bone metastases remain a common feature of advanced cancers and are associated with significant morb...
Bone is one of the most preferential target site for cancer metastases, particularly for prostate, b...
The survival rate for metastatic osteosarcoma has not improved for several decades, since the introd...
Treating metastatic osteosarcoma (OS) remains a challenge in oncology. Current treatment strategies ...
International audienceOsteosarcoma is the most frequent malignant primary bone tumor characterized b...
Metastases of osteosarcomas are heterogeneous. They may grow simultaneously with the primary tumor, ...
Osteosarcoma (OS) is a bone cancer mostly occurring in pediatric population. Current treatment regim...
Abstract Osteosarcoma (OS) is one of the most prevalent malignant cancers with lower survival and po...
Osteosarcoma is the most frequent malignant primary bone tumor characterized by a high potency to fo...
Osteosarcoma is the most common primary malignancy of bone. It arises in bone during periods of rapi...
Bone metastases development requires multistep and multicellular machinery consisting not only of pr...
Osteosarcoma is the most common primary malignancy of bone. It arises in bone during periods of rapi...
Osteosarcoma is the most common primary malignancy of bone. It arises in bone during periods of rapi...
Osteosarcoma (OS) is a class of cancer originating from bone, mainly afflicting children or young ad...
Osteosarcoma (OS) is the most common type of primary solid tumor that develops in bone. Although sta...
Bone metastases remain a common feature of advanced cancers and are associated with significant morb...
Bone is one of the most preferential target site for cancer metastases, particularly for prostate, b...
The survival rate for metastatic osteosarcoma has not improved for several decades, since the introd...
Treating metastatic osteosarcoma (OS) remains a challenge in oncology. Current treatment strategies ...
International audienceOsteosarcoma is the most frequent malignant primary bone tumor characterized b...
Metastases of osteosarcomas are heterogeneous. They may grow simultaneously with the primary tumor, ...
Osteosarcoma (OS) is a bone cancer mostly occurring in pediatric population. Current treatment regim...
Abstract Osteosarcoma (OS) is one of the most prevalent malignant cancers with lower survival and po...
Osteosarcoma is the most frequent malignant primary bone tumor characterized by a high potency to fo...
Osteosarcoma is the most common primary malignancy of bone. It arises in bone during periods of rapi...
Bone metastases development requires multistep and multicellular machinery consisting not only of pr...
Osteosarcoma is the most common primary malignancy of bone. It arises in bone during periods of rapi...
Osteosarcoma is the most common primary malignancy of bone. It arises in bone during periods of rapi...
Osteosarcoma (OS) is a class of cancer originating from bone, mainly afflicting children or young ad...
Osteosarcoma (OS) is the most common type of primary solid tumor that develops in bone. Although sta...
Bone metastases remain a common feature of advanced cancers and are associated with significant morb...
Bone is one of the most preferential target site for cancer metastases, particularly for prostate, b...
The survival rate for metastatic osteosarcoma has not improved for several decades, since the introd...